You are here: Media
Newsletter signup
Click here to sign up for news and updates.
Press Releases
ELAN DRUG TECHNOLOGIES WELCOMES THE LAUNCH OF MS DRUG AMPYRA™ (DALFAMPRIDINE) EXTENDED RELEASE TABLETS
AMPYRA™ USES ELAN’S PROPRIETARY MXDAS™ (MATRIX DRUG ABSORPTION SYSTEM) DRUG DELIVERY TECHNOLOGY ...
Elan Drug Technologies Welcomes the NDA Approval of MS Drug AMPYRA(TM) (Dalfampridine) Extended Release Tablets
AMPYRA(TM) APPROVED USING ELAN'S PROPRIETARY MXDAS(TM) (MATRIX DRUG ABSORPTION SYSTEM) DRUG DELIVERY TECHNOLOGY
ELAN DRUG TECHNOLOGIES CELEBRATES 40 YEARS OF DRUG DELIVERY LEADERSHIP
DUBLIN, IRELAND, December 18th, 2009, Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) ...
Calendar of Events
February 25-26, 2010
Drug Repositioning and Product Pipeline Enhancement
...
March 8-10, 2010
BioEurope Spring 2010
...
March 7-11, 2010
Society of Toxicology annual meeting
...
April 21-23
CPhI, Japan 2010
...
Key Facts
Corporate fact sheet
A high level look at Elan Drug Technologies
past, present and future.
More information
Commercialised products
Information on Elan Drug Technologies
commercialised products.
More information
Elan Corporation, plc. Registered Office: Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland. Registered in Ireland, Number 30356.